lactose has been researched along with pulmicort in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.00) | 18.2507 |
| 2000's | 16 (32.00) | 29.6817 |
| 2010's | 29 (58.00) | 24.3611 |
| 2020's | 4 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Adelroth, E; Dahlbäck, M; Ellis, R; O'Byrne, PM; Stevens, WH; Wattie, J; Woolley, MJ | 1 |
| Bergström, K; Karhu, M; Kauppinen, T; Kuikka, J; Vidgren, M | 1 |
| Harjunen, P; Järvinen, K; Lankinen, T; Lehto, VP; Martimo, K; Paronen, P; Suihko, E | 1 |
| Edge, S; Price, R; Staniforth, JN; Young, PM | 1 |
| de Boer, AH; Frijlink, HW; Gjaltema, D; Goede, J; Hagedoorn, P | 3 |
| de Boer, AH; Frijlink, HW; Gjaltema, D; Goede, J; Hagedoorn, P; Kussendrager, KD | 1 |
| Clark, A; Palakodaty, S; Schiavone, H; Tzannis, ST; York, P | 1 |
| Begat, P; Morton, DA; Price, R; Staniforth, JN | 2 |
| de Boer, AH; Frijlink, HW; Gjaltema, D; Hagedoorn, P | 1 |
| de Boer, AH; Frijlink, HW; Hagedoorn, P; Heijerman, HG; Le Brun, PP; Westerman, EM | 1 |
| de Boer, AH; Dickhoff, BH; Frijlink, HW; Lambregts, D | 1 |
| Caron, V; Descamps, M; Dudognon, E; Willart, JF | 1 |
| Harris, H; Jones, MD; Kaerger, JS; Price, R; Shur, J | 1 |
| Barham, AS; Corrigan, OI; Healy, AM; McDonald, BF; Nolan, LM; Tajber, L | 1 |
| Andersson, P; Edsbäcker, S; Ewing, P; Gerde, P; Ryrfeldt, A; Sjöberg, CO | 1 |
| Hassan, MS; Lau, R | 2 |
| Bur, M; Huwer, H; Lehr, CM; Muys, L | 1 |
| Edge, S; Kaerger, JS; Pitchayajittipong, C; Price, R; Shur, J | 1 |
| Donovan, MJ; Smyth, HD | 1 |
| Carr, AG; Foster, NR; Mammucari, R | 1 |
| Donovan, MJ; Marek, SR; Smyth, HD | 1 |
| Donovan, MJ; Kim, SH; Raman, V; Smyth, HD | 1 |
| Berkland, C; El-Gendy, N; Pornputtapitak, W | 1 |
| Elsayed, I; Elshafeey, AH; Yehia, SA | 1 |
| Berg, E; Fransson, M; Thalberg, K | 1 |
| Hipkiss, D; Kubavat, HA; Price, R; Ruecroft, G; Shur, J | 1 |
| Berkland, C; El-Gendy, N; Selvam, P; Soni, P | 1 |
| Cordts, E; Steckel, H | 1 |
| Dorkoosh, F; Emami, J; Mahzouni, P; Minaiyan, M; Rahmani, N; Tavakoli, N; Varshosaz, J | 1 |
| Hebbink, G; Kinnunen, H; Peters, H; Price, R; Shur, J | 2 |
| Collins, E; Forbes, B; Hammond, RB; Jaffari, S; Martin, GP; Murnane, D; Pencheva, K; Pickering, J; Ramachandran, V; Roberts, KJ; Soufian, M | 1 |
| Hebbink, G; Huck, D; Kinnunen, H; Makein, L; Peters, H; Price, R | 1 |
| Bemelmans, NL; Durham, PG; Hickey, AJ; Ziffels, S | 1 |
| Bäckman, P; Da Silva, E; Koponen, IK; Larsen, ST; Levin, M; Sørli, JB; Thomsen, BL | 1 |
| Liang, ZL; Mao, SR; Muenster, U; Ni, R; Wang, XH; Zhang, L | 1 |
| Buckton, G; Jones, MD | 1 |
| Chan, HK; Maver, U; Planinšek, O; Saboti, D | 1 |
| Folestad, S; Petersson, G; Quayle, MJ; van Ommen, JR; Zhang, D | 1 |
| Akrivou, M; Bouropoulos, N; Eleftheriadis, GK; Fatouros, DG; Tsibouklis, J; Vizirianakis, IS | 1 |
| Björn, IN; Nguyen, D; Remmelgas, J; Thalberg, K; van Wachem, B | 1 |
| Birk, G; Hertel, N; Scherließ, R | 1 |
| Balogh Sivars, K; Bates, S; Brännström, M; Ewing, P; Folestad, S; Franek, F; Horndahl, J; La Zara, D; Petersson, G; Quayle, MJ; Sun, F; van Ommen, JR; Zhang, F | 1 |
| Green, PHR; Ko, CW; Paski, S; Rubio-Tapia, A | 1 |
| Costello, M; Koleng, JJ; Ren, A; Smyth, HDC; Spahn, JE; Zhang, F | 1 |
1 review(s) available for lactose and pulmicort
| Article | Year |
|---|---|
AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.
Topics: Albumins; Atrophy; Budesonide; Celiac Disease; Enteropathy-Associated T-Cell Lymphoma; Glutens; Humans; Inflammatory Bowel Diseases; Lactose; Micronutrients; Prednisone; Receptors, Antigen, T-Cell; United States | 2022 |
2 trial(s) available for lactose and pulmicort
| Article | Year |
|---|---|
Pulmonary deposition of lactose carriers used in inhalation powders.
Topics: Administration, Inhalation; Adult; Bronchodilator Agents; Budesonide; Cross-Over Studies; Drug Carriers; Excipients; Humans; Isotope Labeling; Lactose; Lung; Male; Organotechnetium Compounds; Particle Size; Powders; Radionuclide Imaging; Radiopharmaceuticals | 2000 |
Pulsatile systems for colon targeting of budesonide: in vitro and in vivo evaluation.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Budesonide; Capsules; Cellulose; Chemistry, Pharmaceutical; Colitis; Colon; Colon, Transverse; Delayed-Action Preparations; Galactans; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Hypromellose Derivatives; Ileum; Lactose; Male; Mannans; Mannosidases; Methylcellulose; Pectins; Peroxidase; Plant Gums; Polygalacturonase; Polymethacrylic Acids; Rabbits; Radiography; Rectum; Stomach; Tablets; Trinitrobenzenesulfonic Acid; Young Adult | 2011 |
47 other study(ies) available for lactose and pulmicort
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effect of inhaled budesonide on ozone-induced airway hyperresponsiveness and bronchoalveolar lavage cells in dogs.
Topics: Acetylcholine; Aerosols; Airway Resistance; Animals; Bronchoalveolar Lavage Fluid; Budesonide; Cell Movement; Dogs; Lactose; Neutrophils; Ozone; Pregnenediones; Respiratory Hypersensitivity | 1994 |
Lactose modifications enhance its drug performance in the novel multiple dose Taifun DPI.
Topics: Budesonide; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery Systems; Drug Stability; Drug Storage; Lactose; Metered Dose Inhalers; Models, Biological; Particle Size; Powders | 2002 |
The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
Topics: Administration, Inhalation; Albuterol; Budesonide; Chemistry, Pharmaceutical; Crystallization; Drug Carriers; Humidity; Lactose; Microscopy, Atomic Force; Microscopy, Electron; Nebulizers and Vaporizers; Powders | 2002 |
Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.
Topics: Adhesives; Administration, Inhalation; Aerosols; Budesonide; Colistin; Drug Carriers; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Technology, Pharmaceutical | 2003 |
Air classifier technology (ACT) in dry powder inhalation. Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation.
Topics: Adhesives; Administration, Inhalation; Aerosols; Budesonide; Crystallization; Drug Carriers; Drug Contamination; Lactose; Nebulizers and Vaporizers; Particle Size; Surface Properties; Technology, Pharmaceutical | 2003 |
Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
Topics: Administration, Inhalation; Albuterol; Budesonide; Chemistry, Pharmaceutical; Chromatography, Supercritical Fluid; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Forecasting; Lactose; Metered Dose Inhalers; Microscopy, Electron, Scanning; Nebulizers and Vaporizers; Particle Size; Powders; United Kingdom | 2004 |
The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy.
Topics: Adhesiveness; Albuterol; Budesonide; Chemistry, Pharmaceutical; Crystallization; Drug Carriers; Lactose; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Powders | 2004 |
Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers.
Topics: Bronchodilator Agents; Budesonide; Calibration; Equipment Design; Excipients; Lactose; Lasers; Microscopy, Electron, Scanning; Nebulizers and Vaporizers; Particle Size; Powder Diffraction; Powders | 2004 |
The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
Topics: Adhesiveness; Administration, Inhalation; Aerosols; Albuterol; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Excipients; Lactose; Microscopy, Electron, Scanning; Nebulizers and Vaporizers; Particle Size; Powders; Spectrophotometry, Ultraviolet | 2004 |
Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
Topics: Adhesiveness; Administration, Inhalation; Aerosols; Albuterol; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Equipment Design; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Surface Properties; Time Factors | 2006 |
Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
Topics: Adhesiveness; Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Equipment Design; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Time Factors | 2006 |
Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bronchodilator Agents; Budesonide; Colistin; Drug Delivery Systems; Equipment Design; Excipients; Lactose; Nebulizers and Vaporizers; Particle Size; Powders; Technology, Pharmaceutical | 2006 |
The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
Topics: Bronchodilator Agents; Budesonide; Drug Carriers; Drug Compounding; Ethanol; Lactose; Nebulizers and Vaporizers; Particle Size; Surface Properties | 2006 |
Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g).
Topics: Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Drug Stability; Excipients; Lactose; Mannitol; Models, Chemical; Sorbitol; Technology, Pharmaceutical; Transition Temperature; Trehalose; Water | 2007 |
The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Excipients; Image Processing, Computer-Assisted; Lactose; Microscopy, Electron, Scanning; Nebulizers and Vaporizers; Particle Size; Powders; Surface Properties | 2008 |
Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Topics: Administration, Inhalation; Aerosols; Budesonide; Carbonates; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Excipients; Lactose; Lung; Microscopy, Electron, Scanning; Microspheres; Models, Biological; Nebulizers and Vaporizers; Particle Size; Porosity; Powder Diffraction; Solutions; Solvents; Surface Properties; Tissue Distribution | 2009 |
Vasoconstriction after inhalation of budesonide: a study in the isolated and perfused rat lung.
Topics: Administration, Inhalation; Animals; Bronchodilator Agents; Budesonide; Female; Lactose; Norepinephrine; Perfusion; Prazosin; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; Vasoconstriction | 2010 |
Feasibility study of pollen-shape drug carriers in dry powder inhalation.
Topics: Administration, Inhalation; Budesonide; Drug Carriers; Drug Compounding; Drug Delivery Systems; Durapatite; Feasibility Studies; Lactose; Particle Size; Pollen; Powders; Rheology; Surface Properties | 2010 |
Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Durapatite; Equipment Design; Lactose; Particle Size; Pollen; Powders; Surface Properties; Technology, Pharmaceutical | 2010 |
Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Topics: Administration, Inhalation; Aerosols; Albuterol; Biological Transport; Bronchi; Bronchodilator Agents; Budesonide; Cell Line; Crystallization; Drug Delivery Systems; Drugs, Generic; Epithelial Cells; Excipients; Humans; Lactose; Nebulizers and Vaporizers; Particle Size; Solubility; Therapeutic Equivalency | 2010 |
Characterisation and functionality of inhalation anhydrous lactose.
Topics: Administration, Inhalation; Aerosols; Budesonide; Chemical Phenomena; Drug Compounding; Excipients; Lactose; Particle Size; Powders; Rheology; Surface Properties; Water | 2010 |
Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
Topics: Administration, Inhalation; Aerosols; Budesonide; Drug Carriers; Drug Delivery Systems; Dry Powder Inhalers; Lactose; Particle Size | 2010 |
Particle formation of budesonide from alcohol-modified subcritical water solutions.
Topics: Bronchodilator Agents; Budesonide; Desiccation; Drug Carriers; Ethanol; Excipients; Lactose; Methanol; Particle Size; Powders; Pressure; Solutions; Solvents; Temperature; Water | 2011 |
Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy. 1: Budesonide and lactose.
Topics: Administration, Inhalation; Budesonide; Lactose; Microscopy, Electron, Scanning; Particle Size; Powders | 2011 |
Dry powder inhaler device influence on carrier particle performance.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Drug Carriers; Dry Powder Inhalers; Equipment Design; Hydrodynamics; Lactose; Particle Size | 2012 |
Nanocluster budesonide formulations enhance drug delivery through endotracheal tubes.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Drug Delivery Systems; Equipment Design; Intubation, Intratracheal; Lactose; Leucine; Nanoparticles; Particle Size; Powders | 2012 |
Modeling dispersion of dry powders for inhalation. The concepts of total fines, cohesive energy and interaction parameters.
Topics: Administration, Inhalation; Algorithms; Anti-Asthmatic Agents; Beclomethasone; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Dry Powder Inhalers; Lactose; Microscopy, Electron, Scanning; Models, Statistical; Particle Size; Powders; Reproducibility of Results; Software | 2012 |
Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Topics: Acetone; Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Colloids; Crystallization; Dimethylformamide; Drug Carriers; Drug Compounding; Dry Powder Inhalers; Elastic Modulus; Lactose; Microscopy, Atomic Force; Nanotechnology; Particle Size; Powders; Solvents; Surface Properties; Technology, Pharmaceutical; Water | 2012 |
Development of budesonide nanocluster dry powder aerosols: preformulation.
Topics: Administration, Inhalation; Aerosols; Budesonide; Chemistry, Pharmaceutical; Drug Stability; Ethanol; Excipients; Glucocorticoids; Lactose; Leucine; Nanoparticles; Nanotechnology; Nebulizers and Vaporizers; Osmolar Concentration; Particle Size; Poloxamer; Powders; Rheology; Sodium Chloride; Surface Properties; Surface Tension; Technology, Pharmaceutical; Time Factors | 2012 |
Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Dry Powder Inhalers; Excipients; Lactose; Particle Size; Permeability; Powders; Rheology | 2012 |
Colon specific delivery of budesonide based on triple coated pellets: in vitro/in vivo evaluation.
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Cellulose; Chemical Phenomena; Citric Acid; Colitis, Ulcerative; Colon; Drug Compounding; Drug Delivery Systems; Excipients; Hydrogen-Ion Concentration; Lactose; Male; Methylcellulose; Particle Size; Rats; Rats, Wistar; Solubility; Tablets, Enteric-Coated | 2012 |
An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
Topics: Administration, Inhalation; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Dry Powder Inhalers; Lactose; Particle Size; Powders; Surface Properties | 2014 |
Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
Topics: Administration, Inhalation; Aerosols; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Dry Powder Inhalers; Lactose; Nebulizers and Vaporizers; Neural Networks, Computer; Particle Size; Powders; Rheology | 2014 |
Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
Topics: Administration, Inhalation; Aerosols; Albuterol; Androstadienes; Budesonide; Chemistry, Pharmaceutical; Chromatography, Gas; Computer Simulation; Crystallization; Drug Delivery Systems; Excipients; Fluticasone; Hydrogen Bonding; Lactose; Lasers; Models, Theoretical; Particle Size; Powders; Static Electricity; Surface Properties | 2015 |
Extrinsic lactose fines improve dry powder inhaler formulation performance of a cohesive batch of budesonide via agglomerate formation and consequential co-deposition.
Topics: Bronchodilator Agents; Budesonide; Capsules; Chemistry, Pharmaceutical; Dry Powder Inhalers; Hypromellose Derivatives; Lactose; Particle Size | 2015 |
In vitro dry powder inhaler formulation performance considerations.
Topics: Albuterol; Anti-Asthmatic Agents; Budesonide; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Dry Powder Inhalers; Excipients; In Vitro Techniques; Lactose; Particle Size; Powders | 2015 |
A Proposed In Vitro Method to Assess Effects of Inhaled Particles on Lung Surfactant Function.
Topics: Administration, Inhalation; Aerosols; Albumins; Biological Products; Bronchodilator Agents; Budesonide; Chemistry, Pharmaceutical; Excipients; Formoterol Fumarate; Lactose; Lung; Nebulizers and Vaporizers; Particle Size; Phospholipids; Pulmonary Surfactant-Associated Proteins; Pulmonary Surfactants; Respiratory System Agents; Risk Assessment; Surface Tension; Terbutaline; Toxicity Tests | 2016 |
[Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
Topics: Administration, Inhalation; Budesonide; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Drug Carriers; Lactose; Particle Size; Powders | 2015 |
Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Topics: Adhesiveness; Administration, Inhalation; Albuterol; Beclomethasone; Budesonide; Chemistry, Pharmaceutical; Chromatography, Gas; Colloids; Drug Carriers; Dry Powder Inhalers; Erythritol; Lactose; Mannitol; Microscopy, Atomic Force; Particle Size; Pharmaceutical Preparations; Powders; Solubility; Terbutaline; Triamcinolone Acetonide | 2016 |
Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Budesonide; Crystallization; Drug Compounding; Dry Powder Inhalers; Equipment Design; Excipients; Freeze Drying; Humans; Lab-On-A-Chip Devices; Lactose; Particle Size; Powders; Ultrasonics | 2017 |
Atomic scale surface engineering of micro- to nano-sized pharmaceutical particles for drug delivery applications.
Topics: Aluminum Oxide; Budesonide; Drug Carriers; Drug Delivery Systems; Lactose; Particle Size; Powders | 2017 |
Polymer-Lipid Microparticles for Pulmonary Delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Budesonide; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Compounding; Drug Liberation; Excipients; Female; Humans; Lactose; Leucine; Male; Mucus; Particle Size; Polyvinyl Alcohol; Pulmonary Surfactants | 2018 |
Towards quantitative prediction of the performance of dry powder inhalers by multi-scale simulations and experiments.
Topics: Aerosols; Budesonide; Computer Simulation; Dry Powder Inhalers; Hydrodynamics; Lactose; Models, Theoretical; Particle Size; Stearic Acids | 2018 |
Particle engineered mannitol for carrier-based inhalation - A serious alternative?
Topics: Administration, Inhalation; Albuterol; Budesonide; Drug Carriers; Dry Powder Inhalers; Lactose; Mannitol; Mechanical Phenomena; Particle Size | 2020 |
Controlled Pulmonary Delivery of Carrier-Free Budesonide Dry Powder by Atomic Layer Deposition.
Topics: Administration, Inhalation; Aerosols; Budesonide; Humans; Lactose; Lung; Particle Size; Powders; Silicon Dioxide | 2021 |
Twin-Screw Continuous Mixing Can Produce Dry Powder Inhalation Mixtures for Pulmonary Delivery.
Topics: Administration, Inhalation; Aerosols; Budesonide; Lactose; Particle Size; Powders | 2023 |